In melanoma, as well as in other solid tumors, the cells within a given tumor exhibit strong morphological, functional and molecular heterogeneity that might reflect the existence of different cancer cell populations, among which are melanoma-initiating cells (MICs) with 'stemness' properties and their differentiated, fast-growing progeny. The existence of a slow-growing population might explain the resistance of melanoma to classical chemotherapies that target fast growing cells. Therefore, elucidating the biologic properties of MICs and, more importantly, the molecular mechanisms that drive the transition between MICs and their proliferating progeny needs to be addressed to develop an efficient melanoma therapy. Using B16 mouse melanoma cells and syngeneic mice, we show that the inhibition of microphthalmiaassociated transcription factor (Mitf), the master regulator of melanocyte differentiation, increases the tumorigenic potential of melanoma cells and upregulates the stem cell markers Oct4 and Nanog. Notably, p27, the CDK inhibitor, is increased in Mitf-depleted cells and is required for exacerbation of the tumorigenic properties of melanoma cells. Further, a slow-growing population with low-Mitf level and high tumorigenic potential exists spontaneously in melanoma. Ablation of this population dramatically decreases tumor formation. Importantly, these data were confirmed using human melanoma cell lines and freshly isolated human melanoma cell from lymph node and skin melanoma metastasis. Taken together our data, identified Mitf and p27 as the key molecular switches that control the transition between MICs and their differentiated progeny. Eradication of low-Mitf cells might be an appealing strategy to cure melanoma.
Introduction
The stochastic Darwinian theory of cancer metastasis, which proposes the selection of the most aggressive, invasive and fast-growing cells arising from the acquisition of pro-metastasis mutations, has been widely accepted (Nowell, 1976) . This theory, however, fails to explain why chemotherapies that target fast-growing cells are particularly inefficient in melanomas. Further, most primary melanomas and skin metastases (stage IV) are heavily pigmented, indicating their commitment through differentiation process. Generally, more differentiated tumors yield more favorable prognoses. Yet, for melanoma, differentiation does not appear to indicate a reduced tumorigenic potential.
Recent observations have led to the hypothesis that tumorigenesis is a plagiarism of embryonic tissue development or adult tissue regeneration in which stem cells assume the central role. Indeed, solid tumors have been demonstrated to contain a subset of cells that are endowed with tumorigenic potential and stem cell properties-that is, the capacity for symmetric and asymmetric division, allowing them to self-renew and to give rise to differentiated progeny (Dalerba and Clarke, 2007) . Notably, these cells, called cancer stem cells or cancer-initiating cells grow slowly but have a high division potential, whereas their short-lived progeny grow faster. The theory of cancer stem cells does not exclude the clonal theory, because cancer stem cells can accumulate mutations.
In melanoma, as well as in other solid tumors, the cells within a given tumor exhibit strong morphological, functional and molecular heterogeneity that might reflect the existence of distinct subpopulations, including cancer stem cells and fast growing tumor cells. Alternatively, tumor heterogeneity might be explained by a dynamic and reversible transition between cancerinitiating cells and their differentiated and fast-growing progeny (see for review, Hoek and Goding, 2010) . Nevertheless, both models imply the existence of slow growing cells within a tumor that can explains the failure of chemotherapeutic treatments for melanoma, because these treatments target fast growing cells.
Collectively, these observations have led clinicians and researchers to reconsider their strategies for melanoma therapies. Instead of developing drugs that kill fast-growing cells, an effort must be made to identify new drugs that target MICs, either to eliminate these cells or to steer MICs to differentiate before treatment with classical therapies. Thus, elucidating the biologic properties of MICs and, more importantly, the molecular mechanisms that drive the transition between MICs and their proliferating progeny needs to be addressed to develop an efficient melanoma therapy.
To avoid the artefacts that might be caused by xenografts in severely immune-compromised mice, we wished to characterize MICs using a mouse melanoma cell model and syngeneic allografts. This approach identified a low-microphthalmia-associated transcription factor (Mitf) population endowed with melanoma initiating cell properties. Importantly, we confirm these results using human melanoma cell lines and freshly isolated human melanoma cells, strengthening the physio-pathological and therapeutic relevance of our data.
Results
Mitf controls the 'stemness' and tumorigenic properties of mouse melanoma cells B16 mouse melanoma cells that were grown in stem cell medium formed spheroids (melanospheres) (Figure 1a ) and had increased tumorigenic potential when injected subcutaneously in C57BL/6J mice ( Figure 1b ). These cells had the hallmarks of stem cells-that is, increased expression of Oct4 and Nanog and decreased expression of differentiation markers, such as tyrosinase and Mitf (messengers and proteins) (Figures 1c and d) . 6 cells grown in normal condition (normal condition medium (NCM)) or in melanospheres (SCM) were injected subcutaneously, and tumor volume was monitored for 12 days (mean volume in mm 3 ±s.e.m.). Picture of representative tumors at 12 days is shown (n ¼ 8 mice, *Po0.05). (c) Mitf, Oct4, Nanog and tyrosinase (Tyro) mRNA from NCM and SCM was measured by quantitative PCR; results are expressed as the mean of three independent experiments (fold induction ± s.d.). Results were normalized to Gapdh. (d) Western blot analysis of Mitf, Oct4, Nanog and tyrosinase protein expression in cells grown in normal condition (NCM) or in melanosphere (SCM). One representative experiment is shown. (e) B16-F10 cells were transfected with siRNA against Mitf (siMitf) or with the scrambled sequence (siScr). Mitf expression was evaluated by immunofluorescence with anti-Mitf antibody (2-4). Nuclei were counterstained with DAPI (1-3). Bar ¼ 20 mM. (f). Relative mRNA levels expression of Mitf, Oct4, Nanog and tyrosinase were assayed by quantitative PCR. Results were normalized using Gapdh (fold induction±s.d.). (g) Western blot analysis of Mitf, Oct4, Nanog and tyrosinase protein expression in cells transfected with siRNA against Mitf (siMitf) or with the scrambled sequence (siScr). ERK2 was used as loading control. (h) Tumorigenicity of cells transfected with siScr or siMitf, was assessed by subcutaneous injection as in (b). Tumor volume was measured after 15 days of injection; results are expressed as the mean of volume in mm 3 ± s.e.m. Pictures of representative tumors are displayed (n ¼ 8 mice, *Po0.05).
As Mitf is the master gene in melanocyte differentiation (see for review, (Cheli et al., 2010) ), we asked whether Mitf silencing was sufficient to induce the melanoma-initiating cell (MIC) phenotype in B16 melanoma cells. Transfection with specific Mitf small interfering (si) RNA led to loss of Mitf expression in more than 95% of the cells (Figure 1e) . Notably, the 'stemness' genes Oct4 and Nanog increased in Mitfdepleted cells, and the expression of tyrosinase, another Mitf target gene (Bertolotto et al., 1998) , was inhibited (Figures 1f and g ). Allograft experiments showed that Mitf-depleted cells gave rise to larger tumors compared with control cells (Figure 1h ), illustrating the increased tumorigenicity of these cells.
Note that the percentage of cells in G0/G1 was markedly increased within these melanospheres (Supplementary Figure 1A ). In melanospheres, we observed decreased expression of Cdk2 and stimulation of p21 (Cdkn1A) and p27 (Cdkn1b) levels (Supplementary Figure 1B ) that might cause cell cycle arrest. Mitf silencing also caused a cell cycle arrest in G0/G1 as shown by fluorescence-activated cell sorting (FACS) analysis and BrdU incorporation experiments (Supplementary Figures 1C and 1E ). Cdk2, a Mitf target gene (Du et al., 2004) , decreased and p27 increased (Supplementary Figure 1D) as previously described (Carreira et al., 2006) . However, the tumors that were formed by injection of B16 cells grown in melanospheres, or depleted of Mitf, were heavily pigmented. As expected, these tumors expressed Mitf and tyrosinase (Supplementary Figure 1F ) and showed strong mitogenic activity, as shown by Ki67 labeling (Supplementary Figure 1G) . Taken together these observations demonstrate that the transient loss of Mitf decreases melanoma cell growth in culture, but is sufficient to favor the development of melanoma tumors in mice.
Mitf depletion increases the number of MICs Unexpectedly, cells that were blocked in G0/G1 were more tumorigenic than proliferating cells. To explain this observation, we hypothesized that at a given time a small percentage of cultured B16 cells have a strong tumorigenic potential and that Mitf silencing increased the number of these cells, endowed with MIC characteristics. Therefore, using carboxyfluorescein diacetate succinimidyl ester (CFSE), a vital dye whose fluorescence intensity decreases by half at each cell division (Lyons et al., 2001) , we studied the division history of cells that arose from B16 cells expressing Mitf or not. In vitro, after CFSE loading, cells were cultured for 4 days and analyzed by FACS.
Most of the B16 cells underwent 3-5 divisions. A small percentage (1%) of cells retained robust CFSE labeling, corresponding to the T0 intensity, indicating that they did not divide (Figure 2a) . Consistent with the cell cycle analysis BrdU incorporation experiments, nearly all of the B16 cells that were transfected with siMitf failed to grow, maintaining initial CFSE labeling.
For in vivo studies, CFSE-loaded B16 cells (5 Â 10 5 ) were injected subcutaneously into C57BL6 mice. Eight days later, tumors were dissociated and cells were subjected to FACS analysis. Most of the control B16 cells underwent 4-6 divisions, whereas 10% divided at least seven times. In tumors that arose from Mitfdepleted B16 cells, 85% of the cells divided 7-9 times (Figure 2b ). Figure 2c showed the efficient Mitf depletion by siMitf. On further calculation, B4000 B16 control cells and 15 000 Mitf-depleted cells divided one or more times (Figure 2d, Supplementary Table 1) . These values can be roughly considered as the number of MICs at the time of injection, indicating that Mitf depletion increased the number of MICs in cultured B16 melanoma cells.
The cells with high proliferative potential, however, constituted the largest portion of the tumor mass. Eight days after injection, 85% of the tumor from Mitfdepleted cells developed from cells that had divided more than six times. On extrapolation at 16 days, more than 95% of the tumor mass that develops from Mitfdepleted B16 cells will be formed by these high-dividing cells, whose population increased 20-fold (434 versus 8800) upon Mitf depletion (Figure 2e, Supplementary Table 2) .
To confirm these results, we performed a limiting dilution assay to assess the number of MICs with a standard method (Hu and Smyth, 2009 ). The average of melanoma initiating cell frequency in Mitf-depleted B16 cells is increased by 18-fold (1/1800 versus 1/31 000) ( Table 1 ). These results demonstrate that Mitf depletion causes a robust increase in the number of MICs.
The p27kip1 upregulation is required for induction of the MIC phenotype Of the proteins that are regulated in siMitf-treated B16 cells, the CDK inhibitor p27kip1 has oncogenic activity that causes stem cell expansion (Besson et al., 2007) . Therefore, we investigated the role of p27 in the increased tumorigenic potential that is induced by Mitf silencing.
First, Mitf and p27 siRNA-mediated double knockdown showed that the inhibition of p27 expression blocked the increase in Oct4 in siMitf-transfected cells (Figure 3a) , but was not sufficient to restore normal cell growth of siMitf-transfected cells (not shown). Noteworthy, p27 depletion reduced markedly the size of tumors obtained with Mitf-depleted cells (Figure 3b ) in C57BL6 mice. We also observed that adenovirus-driven p27 overexpression increased Oct4 and Nanog levels ( Figure 3c ). Further, B16 cells infected with p27 adenovirus formed 12 days after injection larger tumors than control adenovirus infected cells (Figure 3d ). Limiting dilution assays showed a ninefold increase in the mean frequency of MICs in p27 overexpressing B16 cells (Supplementary Table 3 ). Collectively, these observations indicate that upregulation of p27 expression is a key event in the induction of the tumorinitiating phenotype that is induced by Mitf silencing, and that p27 by itself is sufficient to favor MICs phenotype.
The Mitf-negative population in mouse melanoma cells is required for tumor formation Next, we asked whether a Mitf-negative population existed in B16 melanoma cells. Flow cytometry analysis after labeling with anti-Mitf showed that roughly 2% of cells did not express Mitf (or expressed very low levels) ( Figure 4a ). This population was sorted, and RNA was extracted and analyzed by quantitative PCR; Mitf and tyrosinase expression was decreased, whereas Oct4 and Nanog mRNA increased (Figure 4b ), suggesting that these cells harbor stem cell properties.
To verify that these cells had MIC-like properties and an exacerbated tumorigenic potential, we attempted to isolate these cells to evaluate their capacity to form tumors in mice. None of the cell surface markers that were previously shown to be expressed on MIC, including CD133, CD44, CD24, Abcg2, Abcb5 and CD271 distinguished the Mitf-negative population (not shown).
In the CFSE-retaining population, the percentage of Mitf-negative cells increased to 20% (Figure 4c , upper right panel), but the Mitf-negative cells represented o0.1% of the CFSE-low population (Figure 4c, upper left panel) . Allograft experiments using the CFSE-high and -low populations showed that tumors developed almost exclusively from the CFSE-high cells (Figure 4c , right, lower panel), whereas the CFSE-low population, which did not contain Mitf-negative cells, failed to form tumors (Figure 4c , left, lower panel). These observations strongly suggest that the endogenous Mitf-negative population has exacerbated melanomainitiating properties. Cells per injection 100 000 10 000 1000 100 SiScr 6/6 2/9 0/6 0/6 1/31000 (1/73000-1/130000) siMitf 6/6 9/9 2/6 1/6 1/1800 (1/4700-1/634) x18
In siMitf transfected cells, melanoma-initiating cells were significantly (*Po0.05) more frequent with an increase of 18 times.
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Further, when the CFSE retaining population (0-1 division) was maintained in culture for 3 weeks and then analyzed again after CFSE labeling, we observed that proportion of CFSE high/CFSE low population was identical to that of the initial population; that is, 5% of CFSE retaining cells. When the same experiment was performed starting with CFSE low population (4/5 divisions), we also observed an almost complete reversion to the initial proportions (Supplementary Figure 2) . The transition from CFSE high to CFSE low seems to be more rapid than the opposite. Indeed, after 2 weeks of culture, the CFSE retaining population has already returned very close to the CFSE-high and CFSE-low proportions observed in the initial culture. However, after 2 weeks, only 0.5% of the CFSE low has reverted to CFSE high. Therefore, there is a dynamic transition between both cell populations that might account for maintenance of the MIC compartment.
Mitf regulates MIC transition in human melanoma cell lines Next, we determined whether Mitf downregulation also occurred in human melanoma spheroids and whether Mitf silencing increased the tumorigenicity of human melanoma cells MeWo) . In these melanoma cell lines, Mitf expression decreased when they were grown in melanospheres, and p27 and Oct4 increased (Figure 5a ). Mitf silencing induced a weak, but consistent increase in p27 and Oct4 protein levels in these cell lines (Figure 5b ). Xenograft experiments showed that Mitf silencing also favored tumor development of MeWo (Figure 5c ) and SKmel28 cells (Figure 5d ), when injected into nude mice. Dilution limit assays showed that Mitf silencing led to a three and 4.5 fold increase in initiating cells frequency in SK-mel28 and MeWo cells, respectively (Supplementary Table 4 ). In MeWo melanoma cells, forced expression of p27 led to larger tumors ( Figure 5e ) and limiting dilution assays with MeWo and SK mel-28 cells showed that infection with p27 expressing adenovirus led to a 3-5-fold increase in the mean frequency of MICs (Supplementary  Table 3 ). These data confirm the key role of p27 in the acquisition of MICs phenotype in human melanoma cells. Under these conditions, 501-Mel cells did not form tumors in nude mice.
Additionally, FACS analysis showed that a Mitfnegative population existed in human melanoma cell lines (Figure 6a ). The CFSE-high population in SKmel28 showed an increase in the Mitf-negative cells (Figure 6b, upper panel) . Xenograft experiments with the CFSE-high and -low populations confirmed that the CFSE-low population containing virtually no Mitf negative cells did not form tumors indicating that the Mitf-negative population was required for tumor formation (Figure 6b , lower panel).
Mitf regulates MIC transition in freshly isolated human melanoma cells Further, to strengthen the physio-pathological relevance of our observations, we have studied the effects of siMitf on human melanoma cells freshly obtained from skin (#1) or lymph node (#2) metastasis. Mitf silencing caused a significant increase in Oct4 and p27 expression ( Figure 7a ) and xenograft experiments showed that cells depleted in Mitf gave rise to larger tumors than control cells (Figure 7b ). Limiting dilution assays showed a 4-5-fold increase in the mean frequency of MICs in Mitf depleted cells compared with control cells (Table 2) . We also performed xenograft experiments with CFSE-low and -high sorted population, using freshly isolated melanoma cells from patient biopsies. Only the CFSEhigh population gave rise to a tumor after 10 weeks with 4/4 tumors for patient #1 and 2/4 tumors for patient #2 (Figures 7c and d) .
Discussion
In this report, we show that Mitf controls the tumorigenic potential of melanoma cells. Indeed, transient Mitf silencing increases melanoma tumor formation in mice. Further, the Mitf-negative population, which exists spontaneously in melanoma cell lines, Mitf is the key molecular switch Y Cheli et al is required for tumor development, and depletion of this population, by cell sorting, restricts melanoma tumor formation.
Notably, the Mitf-negative population contains slowgrowing cells that express high levels of Oct4 and Nanog and low levels of differentiation markers, such as tyrosinase. These hallmarks resemble the properties of stem cells, suggesting that Mitf controls the transition between MICs and their more differentiated and rapidly growing progeny.
Although a previous report has shown that Mitf levels are not significantly affected in human melanoma cells that are grown in spheroids (Fang et al., 2005) , we consistently observed decreased Mitf expression in spheroids that were formed by mouse or human melanoma cells, except in A375 cells that already expressed minute Mitf levels under classical culture conditions (not shown). The loss of Mitf in melanoma spheroids is consistent with the concomitant decreased expression of differentiation markers that was observed by Fang et al., 2005 . Melanoma cells that are grown in spheroids and those that are transfected with siMitf experience a block in G0/G1, and CFSE experiments showed that Mitf-depleted cells, upon siRNA transfection, do not divide. On injection into mice, however, these cells grew faster to form larger melanoma tumors. Mitf silencing leads to a 20-fold increase in the initial number of cells that undergo more than six divisions. These cells might be considered as the MICs, because after 15 days, more than 90% of the tumor mass will be formed by progeny cells originating from these MICs. Further, a small percentage of cells divided once or twice and retained a robust CFSE signal. These cells might represent the pool of MICs that is maintained in vivo and is necessary for further tumor expansion. These results obtained with CFSE method have been confirmed by limiting dilution assay, the gold standard method for the determination of cancer initiating cell number.
In culture, siMitf induced prolonged Mitf silencing and cell cycle arrest, up to 6 days after transfection indicating that under these conditions, Mitf is required for melanoma cell growth, as reported (Du et al., 2004; Carreira et al., 2006) . Further, melanoma cells in which Mitf was constitutively silenced (ensuing transduction with lentivirus encoding for shRNA to Mitf) do not form tumors when injected in mouse (not shown), indicating that Mitf re-expression is required to form melanoma tumor growth. Indeed, Mitf was expressed in the smallest detectable tumors. Therefore, how can we explain that in mice, these Mitf-depleted cells were able to give rise to larger tumors? It should be hypothesized that Mitf depleted cells are able to divide when injected in mice, leading to siRNA dilution, re-expression of Mitf and giving rise to fast growing Mitf expressing cells. These observations suggest that the microenvironment in mice allows to some extent the growth of Mitf-depleted melanoma cells. However, this is an artifactual experimental situation. Indeed, in physiopatological conditions, melanoma tumors contain spontaneously a small population of Mitf negative cells, which can readily give rise to a Mitf expressing progeny without necessary requiring division. How the pool of Mitf negative melanoma cells are maintained in tumors in vivo remain to be elucidated. It can be proposed that tumor micro-environment supports the growth of these cells. The nature of the signal that allows the growth of Mitf-negative melanoma cells growth is unknown, but Mitf has been shown to mediate the antiproliferative effect of transforming growth factor-b (TGFb) (Hoek et al., 2008) . Thus, we hypothesize that activation of the TGFb pathway, by TGFb or Nodal (Strizzi et al., 2008) , regulates the growth of Mitf-depleted cells. Alternatively, the Mitf negative population can derive from the Mitf expressing population itself through a simple dedifferentiation process that will not require the division of the Mitf negative melanoma cells. TGFb also inhibits the differentiation of melanocytes and melanoma cells by preventing PAX3 and Mitf expression (Yang et al., 2008) . Consequently, activation of the TGFb pathway might also be responsible for the loss of Mitf in melanoma spheroids, in vitro and in melanoma tumors, in vivo. This hypothesis is supported by recent findings demonstrating that TGFb signaling allows a decrease in Mitf expression and the maintenance of normal melanocyte stem cells (Nishimura et al., 2010) . Extracellular signals, including WNT (Larue and Delmas, 2006) , cyclic adenosine monophosphate elevating agents (Busca and Ballotti, 2000) , endothelin and stem cell factor are known to regulate Mitf expression. All these agents can modulate Mitf expression, the number of Mitf-negative cells and the number of MICs. Interestingly, BRN-2 (POU3F2), which belongs with Oct4 (POU5F1) to the POU domain transcription factor family, functions at the cross road between ERK and WNT pathways. BRN-2 identifies in some melanoma, a population of Mitf negative cells with increased invasive properties (Goodall et al., 2008) . Intravital imaging study revealed a reversible switching between poorly differentiated, BRN-2-high and highly pigmented BRN-2-low melanoma cells (Pinner et al., 2009) . The BRN-2-high cells might identify the MICs population, but we did not observe a consistent increase in BRN-2 expression in the Mitf-negative population in both cultured cells and in B16 or human tumors obtained after injection in mice (Supplementary Figure 3) .
Taken together, the above observations underpin the notion of heterogeneity and plasticity of MICs, indicating that the MICs number certainly varies during the tumor history. Indeed, at a given time there is a hierarchical organization, as all the cells do not display equivalent capacity to form tumors. However, we also showed that this hierarchy is not fixed and that MICs can arise probably from their own progeny without necessary asymmetric division as hypothesized by Hoek and Goding (Hoek and Goding, 2010) . Interestingly, a very recent report (Roesch et al., 2010) also described a subpopulation of temporally slow-cycling melanoma cells that is required for tumor development. This population expresses high level of H3K4 histone demethylase, JARID1B that is dynamically regulated as it is the case for Mitf. It should be noted that we did not observe a consistent increase in JARID1B expression in the Mitf low population, but we observed a striking regulation of the enzymes involved in the methylation/demethylation processes (not shown).
Other pathways, such as Notch (Schouwey and Beermann, 2008) , and hedgehog (Stecca et al., 2007) , which also regulate melanoma development, as well as environmental stresses, such as hypoxia and acidosis might have a key role in the transition between melanoma initiating cells and their progeny and deserve to be investigated in this context.
In the first part of this manuscript, the data were generated with B16 mouse melanoma cells and a syngeneic allograft model using C57/BL/6J mice. In doing so, we avoided interspecies immune responses but maintained a fully responsive immune system against tumor cells. This situation is similar to what occurs in human patients who develop melanoma tumors and can be considered more representative of human pathophysiology than the xenograft model in highly immunocompromised mice that was used by Quintana et al. (2008) .
At the molecular level, we made the same observations using human melanoma cell lines, in which we observed a loss of Mitf when they were grown in spheroids and induction of Oct4 in Mitf-depleted cells. We confirmed in human melanoma cells that Mitf-negative cells are required for (or at least greatly favor) tumor development, although we are aware of the limitations of the xenograft model using partially immunodeficient mice. Regardless of the name (melanoma stem cells, MICs) or the proportion of these undifferentiated and highly metastatic cells within a tumor, their existence should no longer be questioned. Irrespective of the percentage of MICs in a tumor, the efficiency of melanoma therapy will rely on its capacity to eradicate this population.
One strategy should specifically kill MICs. This approach would not result in a spectacular short-term effect if the proportion of MICs is low but might lead to the progressive loss of the growth potential of the tumors. A recent report identified salinomycin as a potential drug that specifically eliminates breast cancer stem cells (Gupta et al., 2009) ; this compound should be evaluated in melanoma cell lines. 6 cells from patient #1 or #2 transfected with siScr or siMitf for 48 h were injected subcutaneously, and tumor volume was monitored for 25 days (mean volume in mm 3 ± s.e.m., n ¼ 8 mice, *Po0.05). (c) Freshly isolated human melanoma cells were labeled with CFSE. After 72 h, cells were sorted using FACSAria for high or low CFSE content (as in Figure 6 ). In all 70 Â 10 3 high-CFSE and low-CFSE cells were subcutaneously injected in right and left side of nude mice, respectively. One representative picture of mouse injected with CFSE-sorted melanoma cells is shown. (d) Sixty days later, mice were killed and tumors were counted. A second strategy would rather favor the transition of MICs toward their more differentiated and fast-growing progeny by activating pathways that regulate melanoma differentiation. This approach appears disadvantageous, because it will increase the number of fast-growing cells, but it will also eliminate the pool of self-renewing cells, or block the transition from fast growing progeny to MICs, resulting in tumor eradication. In agreement with this hypothesis, ectopic expression of Mitf, in SKMel28 melanoma cells, was reported to block the tumorigenic capacity in these cells (Carreira et al., 2006) . This approach that is a reminiscence of the differentiation therapy used for leukemia (Spira and Carducci, 2003) , could provide a pharmacological strategy to eliminate MICs, and to improve the treatment of melanoma. Beside melanoma, our results will foster the evaluation of differentiation master genes in the regulation of the behavior of other cancer initiating cells and might help to the unification of cancer-initiating cell, tumor cell plasticity and phenotype switching paradigms.
Materials and methods
Cell culture B16-F10 mouse melanoma cells and 501-Mel human melanoma cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 7% fetal bovine serum (Invitrogen) and penicillin/streptomycin (100 IU/50 mg/ml (Invitrogen). MeWo and Sk-Mel-28 human melanoma cells were grown in Roswell Park Memorial Institute media 1640 (Invitrogen), with the same supplements. Melanospheres from these cell lines were obtained by culturing the cells in mouse embryonic fibroblast-conditioned medium (R&D systems, Minneapolis, MN, USA) supplemented with 4 ng/ml of basic fibroblast growth factor (Promega, Madison, WI, USA) as described previously (Fang et al., 2005) . Cells were transfected with siRNA against Mitf (Larribere et al., 2005) , p27 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a scrambled sequence using Lipofectamine RNAiMax (Invitrogen) according manufacturer protocol. In brief, 8 Â 10 4 cells were seeded in six-well plates for 24 h, transfected with 5 ml of Lipofectamine and 50 nM of siRNAs and incubated for 48 h before processing. For double siRNA knockdown, Mitf and p27 siRNA were used at 50 nM and completed to 100 nM with appropriated scrambled siRNA. Cells infection with adenovirus expressing p27 (vector biolabs, Philadelphia, PA, USA) or the control adenovirus (empty vector) was carried out as described elsewhere (Larribere et al., 2004) .
Antibodies and reagents
Antibodies against Oct4, ERK2, Gapdh, p27, Hsp60, were from Santa Cruz Biotechnology. Anti Ki-67 antibody was from BD Biosciences (Franklin Lakes, NJ, USA). Anti Cdk2 and p21 antibodies were from Cell Signaling Technology (Boston, MA, USA). Nanog antibody was purchased from Abcam (Cambridge, MA, USA) and anti-Mitf (C5) from Spring bioscience (Pleasanton, CA, USA). Secondary alexa488-, alexa596-, PE-conjugated antibodies, propidium iodide, DAPI, CellTrace CFSE cell proliferation kit were from Invitrogen. Deoxyribonuclease I and dispase were purchased from Sigma-Aldrich (Saint Louis, MO, USA) and collagenase A from Roche Applied Sciences (Indianapolis, IN, USA) .
Western blot
Cells were solubilized for 10 min at 4 1C, in buffer containing, 50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, EDTAfree protease inhibitor cocktail from Roche Applied Science. Tumors were cut in small pieces and extracts were prepared with the previous buffer in a dounce tissue grinder. Then, 30-60 mg of proteins were separated by electrophoresis on 10% polyacrylamide SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Immobilon, Millipore, Molsheim, France). The membrane was saturated for 1 h at 25 1C in 10 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% Tween 20, 3% bovine serum albumin (weight/volume) and 5% gelatin (weight/volume). The primary antibody was incubated for 18 h at 4 1C. After three washes of 10 min in10 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, the secondary antibody coupled with horse radish peroxidase (Dakopatts, Glostrup, Denmark) was then incubated for 1 h at 25 1C. After three additional washes, proteins of interest were revealed by ECL (Amersham, Uppsala, Sweden).
In vivo mouse tumor model Animal experiments were carried out in accordance with the Declaration of Helsinki and were approved by a local ethical committee. Female immune-deficient BALB/c nu/nu (nude) mice and C57BL6J mice were obtained at 6 weeks of age from Harlan Laboratory (Gannat, France). Animals were maintained in a temperature-controlled facility (22 1C) on a 12-h light/dark cycle and were given free access to food (standard laboratory chow diet from UAR, Epinay-S-Orge, France).
Mice were inoculated subcutaneously with melanoma cells (0.5 Â 10 6 B16 F10 cells or 2 Â 10 6 MeWo or Sk-Mel-28 per injection in 200 ml of phosphate-buffered saline). The growth tumor curves were determined by measuring the tumor volume using the equation V ¼ (L Â W 2 )/2 as previously described (Botton et al., 2009 ). Mice were killed by CO 2 inhalation and tumors were removed and frozen for immuno-fluorescence studies or analyzed by western blots.
CFSE labeling
For the in vitro CFSE assay, cells were labeled with 10 mmol/l of CFSE according to the manufacturer's protocol (Invitrogen), then plated and transfected with Lipofectamine RNAiMax according to the manufacturer's protocol. Cells were detached and analyzed by flow cytometry using FACSCalibur (BD biosciences). For in vivo assay, cells were first transfected with siRNA for 48 h, detached from the plates with 3 mM EDTA in phosphate-buffered saline, and labeled with 10 mmol/l of CFSE according to the manufacturer's protocol (Invitrogen) previous subcutaneous injections. Mice were killed 192 h after injection for tumor analysis. Tumors were dissociated for 2 h with a mix of collagenase A (0.33 U/ml), Dispase (0.85 U/ml) and DNase I (144 U/ml) in RPMI medium and analyzed by FACScan. The number of initiating cells was determined as described (Lyons et al., 2001) .
Flow cytometry and fluorescence-activated cell sorting Cells exposed to siMitf, siScr or melanospheres were detached in phosphate-buffered saline/EDTA 1 mM, fixed in citrate buffer (250 mM sucrose, 40 mM tri sodium citrate pH7.6) for at least 30 min at À20 1C and stained with 40 mg/ml of propidium iodide for 45 min. Fluorescence was measured by using the FL2 channels of a BD FACScan (Becton Dickinson, Cowley, UK) and data was analyzed with CellQuest software (Becton Dickinson, Cowley, UK).
FACS was performed on a BD FACSAria flow cytometer (BD biosciences). Briefly, cells were fixed in 70% ethanol for 10 min on ice then washed with 1% bovine serum albumin in phosphate-buffered saline and incubated for 30 min on ice with Mitf antibody. After a wash, cells were incubated for 20 min on ice with secondary fluorescein isothiocyanate conjugated anti mouse antibody then washed once and immediately processed for cell sorting. Sorted cells were then lyzed using the RNAeasy miniprep kit (Qiagen, Valencia, CA, USA) according to manufacturer's protocol and then reverse transcriptase and quantitative PCR were performed. BrdU incorporation was performed with 'in situ cell proliferation kit' according to manufacturer's recommendations, and analyzed with a BD FACScan.
Reverse transcription and quantitative PCR Total cell RNA was extracted using the RNAeasy miniprep kit (Qiagen), according to the manufacturer's instructions, and 1 mg of RNA was reverse amplified using oligo dT using reverse transcription system (Promega), according to manufacturer's instructions. PCR was performed using StepOnePlus real time PCR system, and the power SYBR green PCR master mix reagent (Applied biosystems, Foster city, CA, USA). Relative quantification of the amplicons was performed by 2(-Delta Delta C(T)) method. Primer list details are available upon request.
Immunocytochemical and immunohistological staining Cells or tissue were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-X-100 and stained with Mitf specific antibodies, or Ki67 PE-conjugated antibody (BD biosciences). Isotype-matched mouse antibodies were used as controls. Mitf was detected using the corresponding Alexa Fluor 594-conjugated secondary antibodies (Invitrogen). Staining was observed by fluorescence microscopy.
Statistical analysis
Results are presented as mean ± s.d. or mean ± s.e.m. for in vivo assay with experiment numbers indicated in the figure legends. Statistical significance was assessed using the Student's t-test. Po0.05 was accepted as statistically significant. Limiting dilution analyses were performed using the Extreme Limiting Dilution Analysis (ELDA) function of the 'StatMod' package (http://bioinf.wehi.edu.au/software/elda/ index.html), part of the R statistical software project (http:// www.r-project.org). MIC frequencies were compared using likelihood ratio tests (Hu and Smyth, 2009) .
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